… who were previously treated with platinum-based regimens responded, and in a phase 2
trial of erlotinib among previously treated patients with non–small-cell lung cancer in which 10 …

… Quality of life (QoL) evaluation, defined as the time to clinically significant deterioration in
three common lung cancer symptoms, showed that patients receiving erlotinib had significantly …

… Symptom improvement in lung cancer patients treated with erlotinib: quality of life
analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. …

… Erlotinib and gefitinib, two small molecular agents that target the tyrosine kinase domain of
the EGFR, were approved in many countries for the treatment … erlotinib, as first-line treatment …

… in the third treatment erlotinib was given daily continuously. A total of 40patients were treated
in these … In contrast, increasing severity of rash in erlotinib-treated lung cancer patients was …

… response to erlotinib; however, those who had never smoked had a significant survival benefit
from erlotinib. To clarify the role of EGFR in the outcome of non–small-cell lung cancer, we …

… Erlotinib is a small molecule inhibitor of epidermal growth … with previously treated advanced
non-small cell lung cancer. Here, … trial of erlotinib (Tarceva Lung Cancer Survival Treatment). …

… Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …

… data on erlotinib in the treatment of advanced NSCLC. … erlotinib is also approved in second-
or third-line treatment for … available data on erlotinib in the treatment of advanced NSCLC. …

… improved survival in the patients treated with single-agent erlotinib, patient preselection based
… valid strategy to save this class of antitumor agents for the treatment of relapsed NSCLC. …